ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021
[Research progress of serum biomarkers for early screening of hepatocellular carcinoma].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multifaceted roles of lactate dehydrogenase in liver cancer (Review).International journal of oncology · 2025Review
- [Study of magnetic resonance imaging based on liver imaging reporting and data system for evaluating phosphatidylinositol proteoglycan-3 expression in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The latest research data shows that the cause of death of liver cancer patients ranks third among malignant tumors. The global situation of early detection, early diagnosis and early treatment of liver cancer is severe. Therefore, how to achieve early diagnosis of liver cancer has important clinical significance. At present, alpha-fetoprotein, alpha-fetoprotein-L3 and des-gamma-carboxythrombin are commonly used in the clinical detection of hepatocellular carcinoma; however, their sensitivity cannot meet the diagnostic needs of patients with early liver cancer. With the development of molecular biology techniques such as serum oligosaccharide chains detection, B10, a member of the aldehyde ketone reductase family, microRNAs, circulating tumor cells, DNA methylation, and other novel serum biomarkers, a new option for the early screening and diagnosis of hepatocellular carcinoma patients will be offered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.